#EikonTherapeutics, former MSD head of R&D #RogerPerlmutter's new project, is hoping to raise up to $318 million from a #Nasdaq listing, in another signal of building confidence in the #biopharma sector.
pharmaphorum.com/news/eikon-p...
pharmaphorum.com/news/eikon-p...
January 28, 2026 at 6:58 PM
#EikonTherapeutics, former MSD head of R&D #RogerPerlmutter's new project, is hoping to raise up to $318 million from a #Nasdaq listing, in another signal of building confidence in the #biopharma sector.
pharmaphorum.com/news/eikon-p...
pharmaphorum.com/news/eikon-p...
Former MSD head of R&D #RogerPerlmutter has continued the swift development track for #cancer #startup #EikonTherapeutics, filing an #IPO to build its already healthy cash position further.
pharmaphorum.com/news/perlmut...
pharmaphorum.com/news/perlmut...
Perlmutter's Eikon follows the IPO trail
Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.
pharmaphorum.com
January 12, 2026 at 11:16 AM
Former MSD head of R&D #RogerPerlmutter has continued the swift development track for #cancer #startup #EikonTherapeutics, filing an #IPO to build its already healthy cash position further.
pharmaphorum.com/news/perlmut...
pharmaphorum.com/news/perlmut...